Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
Nurix Therapeutics (Nasdaq: NRIX) announced plans to present at the 5th Annual TPD Summit from October 25-28, 2022, in Boston, MA. A Keynote Plenary will be delivered by Arthur T. Sands, M.D., Ph.D., the CEO, discussing advancements in BTK degraders for hematologic malignancies. Other presentations include topics on targeted protein degradation and orally active, brain-penetrant degraders. Nurix focuses on developing therapies that modulate cellular protein levels, utilizing their DELigase discovery platform.
- Keynote presentation at a major industry summit enhances company visibility.
- Focus on innovative approaches to cancer treatment via targeted protein modulation.
- Proprietary DELigase platform may lead to novel drug candidates.
- None.
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it will make several presentations, including a Keynote Plenary presentation by Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, at the 5th Annual TPD Summit which is being held October 25‒28, 2022, in Boston, MA.
Presentation Details:
Title: The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic
Speaker: Arthur T. Sands, MD., Ph.D., president and chief executive officer
Date and Time: Wednesday, October 26, 2022, 10 a.m. ET
Title: Utilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation
Speaker: Christopher B. Phelps, Ph.D., vice president and head of early discovery
Date and Time: Wednesday, October 26, 2022, 12 p.m. ET
Title: Discovery of Orally Active, Brain-Penetrant, Targeted Protein Degraders
Speaker: Ryan B. Rountree, Ph.D., executive director, preclinical pharmacology
Date and Time: Wednesday, October 26, 2022, 1 p.m. ET
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
| Investors: | Media: |
| Elizabeth Wolffe, Ph.D. | Brett Whelan |
| Wheelhouse Life Science Advisors | LifeSci Communications |
| lwolffe@wheelhouselsa.com | bwhelan@lifescicomms.com |
FAQ
What is Nurix Therapeutics presenting at the 5th Annual TPD Summit?
When is Nurix’s Keynote Plenary presentation scheduled?
What topics will be covered in the presentations by Nurix at the summit?
What is the significance of Nurix's DELigase platform?
